Uniplar Capsule

Uniplar Capsule 1 mcg

Uniplar Capsule 1 mcg is a medication used to help balance calcium and phosphorus levels in the blood. It is commonly prescribed to treat complications that arise from chronic kidney disease, such as hyperphosphatemia, secondary hyperparathyroidism, and vitamin D deficiency. Uniplar Capsule 1 mcg works by activating vitamin D receptors, which stimulate the production of proteins that cause phosphorus and calcium to be removed from the bloodstream and deposited into the bones.

Uses of Uniplar Capsule 1 mcg

Uniplar Capsule 1 mcg is used to treat complications of chronic kidney disease, such as elevated levels of phosphorus in the blood (hyperphosphatemia), high calcium levels in the blood (hypercalcemia), and low levels of vitamin D (vitamin D deficiency). Uniplar Capsule 1 mcg can also help to lower the activity of the body’s parathyroid hormone (PTH), which helps to regulate the balance of calcium and phosphorus in the body.

Brand Name	Uniplar
Type	Capsule
Weight	1 mcg
Generic	Paricalcitol
Manufacturer	UniMed UniHealth Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Uniplar Capsule 1 mcg works by activating vitamin D receptors, which stimulates the production of proteins that cause calcium and phosphorus to be removed from the bloodstream and deposited into the bones. This helps to regulate the balance of calcium and phosphorus in the body and reduce the level of active parathyroid hormone (PTH).

How Long Does it Take to Work?

The effects of Uniplar Capsule 1 mcg are usually seen within the first few days of treatment. It may take several weeks for the full effects to be noticed.

Absorption

Uniplar Capsule 1 mcg is rapidly and almost completely absorbed following oral administration.

Route of Elimination

Uniplar Capsule 1 mcg is eliminated mainly through the kidneys and is not metabolized in the body.

Dosage

Paricalcitol capsules may be taken without regard to food. Chronic Kidney Disease (CKD) Stages 3 and 4 in Adults: Administration of Paricalcitol soft gel capsules orally once daily or three times a week. When dosing three times weekly, do not administer more frequently than every other day.

Initial Dose: Recommended Paricalcitol Starting Dose Based Upon Baseline PTH Level-

Baseline intact parathyroid hormone (IPTH) Level: <500 pg/ml

Daily Dose: 1 mcg
Three Times a Week Dose*: 2 mcg

Baseline intact parathyroid hormone (IPTH) Level: >500 pg/ml

Daily Dose: 2 mcg
Three Times a Week Dose*: 4 mcg

Dose Titration: Recommended Paricalcitol Dose Titration Base upon IPTH Level-

IPTH Level Relative to Baseline: The same, increased or decreased by less than 30%

Daily Dose: Increase dose by 1 mcg
Three Times a Week Dose*: Increase dose by 2 mcg

IPTH Level Relative to Baseline: Decreased by more than or equal to 30% and less than or equal to 60%

Daily Dose: Maintain dose
Three Times a Week Dose*: Maintain dose

IPTH Level Relative to Baseline: Decreased by more than 60% or iPTH less than 60 pg/ml

Daily Dose: Decrease dose by 1 mcg
Three Times a Week Dose*: Decrease dose by 2 mcg

*To be administered not more often than every other day.

If a patient is taking the lowest dose, 1 mcg, on the daily regimen and a dose reduction is needed, the dose can be decreased to 1 mcg three times a week. If a further dose reduction is required, the drug should be withheld as needed and restarted at a lower dosing frequency.

Chronic Kidney Disease Stage 5 in Adults:

Initial Dose: Administer the dose of Paricalcitol capsules orally three times a week, no more frequently than every other day based upon the following formula: Dose (micrograms) baseline PTH (Pg/ml) divided by 80. Treat patients only after their baseline serum calcium has been adjusted to 9.5 mg/dL or lower to minimize the risk of hypercalcemia.

Dose Titration: Individualize and titrate Paricalcitol dose based on iPTH, serum calcium and phosphorus levels to maintain an iPTH level within target range. Every 4 weeks, each administered Paricalcitol dose may be increased in 1 mcg increments, maintaining the three times per week regimen (e.g., Increase from 1 mcg three times per week to 2 mcg three times per week), At any time, each administered dose may be decreased by 1 mcg. Paricalcitol may be stopped if the patient requires reduction while receiving 1 mcg three times per week, resuming when appropriate.

CKD Stage 5 Initial Dose-

Administer the dose of Paricalcitol capsules orally three times a week, no more frequently than every other day based upon the following formula:Dose* (micrograms) = baseline iPTH (pg/mL) divided by 120 ( Round down to the nearest whole number )

Dose Titration: Subsequent dosing should be individualized and based on IPTH, serum calcium and phosphorus levels to maintain an iPTH level within target range. Every 4 weeks, each administered Paricalcitol dose may be increased in 1 mcg increments, maintaining the three times per week regimen (e.g., increase from 1 mcg three times per week to 2 mcg three times per week). At any time, each administered dose may be decreased by 2 meg. Paricalcitol may be stopped if the patient requires reduction while receiving 2 mcg three times per week or 1 mcg three times per week, resuming when appropriate.

Monitoring: Monitor serum calcium and phosphorus levels closely after initiation of Paricalcitol, during dose titration periods and during co-administration with strong CYP3A inhibitors. If hypercalcemia is observed, the dose of Paricalcitol should be reduced or withheld until these parameters are normalized.

The usual starting dose of Uniplar Capsule 1 mcg is 0.04-0.06 mcg/kg/day. The individual’s condition should be closely monitored and the dosage adjusted to achieve the desired effect. It is important to take Uniplar Capsule 1 mcg exactly as prescribed by the physician and not to alter the dosage in any way.

Administration

Uniplar Capsule 1 mcg should be taken orally, ideally once daily or as directed by the physician. The tablet should be taken with or without food. Uniplar Capsule 1 mcg should not be split, crushed or chewed.

Side-Effect

Common side effects of Uniplar Capsule 1 mcg include upset stomach, vomiting, diarrhea, constipation, headaches, dizziness and rash. Less common side effects include fluid retention, difficulty breathing, chest pain, and muscle/ joint pain.

Toxicity

Uniplar Capsule 1 mcg is generally well tolerated and has a low risk of toxicity. Mild side effects may occur but usually go away with continued use of the medication.

Precaution

Patients with kidney disease, liver disease, and certain allergies should be monitored closely while using Uniplar Capsule 1 mcg, as it can cause an allergic reaction in some people. Additionally, patients with low levels of calcium in their blood or those taking other drugs that can interact with Uniplar Capsule 1 mcg should also be monitored closely. It is important to tell the doctor about all other medications you are taking so that potential interactions can be avoided.

Interaction

Uniplar Capsule 1 mcg may interact with certain other medications, such as diuretics, non-steroidal anti-inflammatory drugs, and certain antibiotics. Additionally, it may interact with certain supplements such as calcium and vitamin D. It is important to tell the doctor about all other medications and supplements you are taking so that potential interactions can be avoided.

Disease Interactions

Uniplar Capsule 1 mcg may interact with diseases such as kidney and liver disease, as well as certain allergies, so it is important to tell the doctor if you are suffering from any of these diseases so that potential interactions can be avoided.

Drug Interactions

Uniplar Capsule 1 mcg may interact with other drugs such as diuretics, non-steroidal anti-inflammatory drugs, and certain antibiotics. It is important to tell the doctor all other medications you are taking, so that potential interactions can be avoided.

Food Interactions

Uniplar Capsule 1 mcg does not interact with food. It is usually taken with or without food.

Pregnancy Use

Uniplar Capsule 1 mcg is not recommended for use in pregnant women unless the potential benefit to the mother outweighs the potential risk to the fetus.
It is important to tell the doctor if you are pregnant or planning to become pregnant before taking Uniplar Capsule 1 mcg.

Lactation Use

Uniplar Capsule 1 mcg is not recommended for use in breastfeeding women due to the potential risk to the baby. It is important to tell the doctor if you are breastfeeding or plan to breastfeed before taking Uniplar Capsule 1 mcg.

Acute Overdose

An overdose of Uniplar Capsule 1 mcg may cause symptoms such as nausea, vomiting, and headache. It is important to seek immediate medical attention if you or someone you know has taken an overdose of Uniplar Capsule 1 mcg.

Contraindication

Uniplar Capsule 1 mcg should not be used to treat patients with primary hyperparathyroidism. It should also not be used in patients who are allergic to Uniplar Capsule 1 mcg or any of its ingredients.

Use Direction

Uniplar Capsule 1 mcg should be taken as prescribed by the doctor. Do not alter the dosage and do not stop taking the medication without consulting the doctor.